2014
DOI: 10.1126/scitranslmed.3008982
|View full text |Cite
|
Sign up to set email alerts
|

Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses

Abstract: Species of Clostridium bacteria are notable for their ability to lyse tumor cells growing in hypoxic environments. We show that an attenuated strain of Clostridium novyi (C. novyi-NT) induces a microscopically precise, tumor-localized response in a rat orthotopic brain tumor model after intratumoral injection. It is well known, however, that experimental models often do not reliably predict the responses of human patients to therapeutic agents. We therefore used naturally occurring canine tumors as a translati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
257
0
4

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 326 publications
(262 citation statements)
references
References 47 publications
1
257
0
4
Order By: Relevance
“…Live Salmonella (ClinicalTrials.gov Identifier NCT01099631), Listeria (ClinicalTrials.gov Identifier NCT01598792; ClinicalTrials.gov Identifier NCT01675765; ClinicalTrials.gov Identifier NCT02002182), and Clostridium (ClinicalTrials.gov Identifier NCT01118819) all have current or recent FDA-sanctioned human clinical studies in the cancer treatment setting. Results of the Clostridium trial have recently been published (Roberts et al, 2014) and demonstrated an anti-tumor response. The preclinical studies of Clostridium also showed antitumor activity in a veterinary trial with pet dogs (Roberts et al, 2014) and an earlier study using Salmonella VNP20009 also showed significant antitumor activity in dogs with spontaneous neoplasms (Thamm et al, 2005).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Live Salmonella (ClinicalTrials.gov Identifier NCT01099631), Listeria (ClinicalTrials.gov Identifier NCT01598792; ClinicalTrials.gov Identifier NCT01675765; ClinicalTrials.gov Identifier NCT02002182), and Clostridium (ClinicalTrials.gov Identifier NCT01118819) all have current or recent FDA-sanctioned human clinical studies in the cancer treatment setting. Results of the Clostridium trial have recently been published (Roberts et al, 2014) and demonstrated an anti-tumor response. The preclinical studies of Clostridium also showed antitumor activity in a veterinary trial with pet dogs (Roberts et al, 2014) and an earlier study using Salmonella VNP20009 also showed significant antitumor activity in dogs with spontaneous neoplasms (Thamm et al, 2005).…”
Section: Discussionmentioning
confidence: 99%
“…Results of the Clostridium trial have recently been published (Roberts et al, 2014) and demonstrated an anti-tumor response. The preclinical studies of Clostridium also showed antitumor activity in a veterinary trial with pet dogs (Roberts et al, 2014) and an earlier study using Salmonella VNP20009 also showed significant antitumor activity in dogs with spontaneous neoplasms (Thamm et al, 2005). Continued success is likely to sustain interest in these novel therapeutic approaches.…”
Section: Discussionmentioning
confidence: 99%
“…Clostridium novyi, a soil-dwelling organism incriminated in wound associated gangrene and infections in intravenous (i.v.) drug users (19), was shown to be important in treating tumors (20)(21)(22)(23). Moreover, Clostridium bifermentans subsp.…”
mentioning
confidence: 99%
“…Bacterial endotoxins (Lipopolysaccharides) and immune-toxins can be used for both destruction of tumor tissue and development of vaccines (26). Bacteria can also be used as vectors for gene therapy and/or administration of anticancer products (27). Spores of anaerobic bacteria can reach and germinate only in oxygen-poor tumor regions and become activated.…”
Section: Microbiology and Cancermentioning
confidence: 99%
“…For example, cytosine deaminase (converting 5-fluorocytosine to 5-fluorouacil) and nitroreductase (transforming CB1954 prodrug to a DNA crosslinking agent) have been utilized in in vitro cancer models using Clostridium sporogenes as a vector and have been shown to kill tumor cells (33). Similarly, another study showed that intratumoral injection of an attenuated strain of C. novyi reduced tumor volume in several preclinical animal models as well as in one phase I study on a human with metastatic disease (27). Salmonella has also been used as a vector in this case for cytosine deaminase and nitroreductase which exhibited anti-cancer effects in vivo (28).…”
Section: Microbiology and Cancermentioning
confidence: 99%